0
0
9/21/23 at 6:00pm
Organization
Targetedonc.com
Author
Nichole Tucker
29 words
0
Comments
The investigational PLK1 inhibitor, CYC140, is the focus of important clinical research in advanced solid tumors, leukemias, and lymphomas.
You are the first to view
https://www.targetedonc.com/view/exploration-of-plk1-inhibition-in-advanced-cancers-begins
Create an account
or login to join the discussion